- Home
- / Oxford BioTherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oxford BioTherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$21.6 M
Revenue
£2.1 M
FY, 2018
CreditSafe Score
?
Score changed on Mar 24, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 427.3K | 293.8K | 429.5K | 2.0M | 3.0M | 4.5M | 2.1M | |
| Cost of goods sold | 82.0K | 125.3K | 117.2K | 157.4K | 480.4K | 438.6K | ||
| Gross profit | 345.3K | 176.7K | 272.1K | 1.5M | 2.6M | |||
| Gross profit margin, % | 80.8% | 60.1% | 63.4% | 76.0% | 85.5% | |||
| Operating expense total | 1.1M | 1.3M | 1.5M | 2.0M | 8.1M | 8.8M | 7.7M | |
| Depreciation and amortization | 139.8K | |||||||
| EBITDA | (1.4M) | (1.3M) | (1.6M) | (6.5M) | (6.1M) | (3.0M) | ||
| EBITDA margin, % | -438.1% | -380.6% | -322.4% | -202.8% | -66.0% | |||
| EBIT | (728.3K) | (1.4M) | (1.4M) | (1.7M) | (6.6M) | (6.3M) | (3.2M) | (6.5M) |
| EBIT margin, % | -170.4% | -462.0% | -400.2% | -328.6% | -207.2% | -69.3% | -312.8% | |
| Interest expense | 1.0M | |||||||
| Pre tax profit | (773.4K) | (1.4M) | (1.4M) | (1.8M) | (6.9M) | (7.0M) | (3.4M) | (7.6M) |
| Income tax expense | 227.0K | 158.5K | 187.6K | 165.2K | 1.2M | 964.4K | 1.1M | (1.1M) |
| Net Income | (546.5K) | (1.3M) | (1.2M) | (1.6M) | (5.6M) | (6.0M) | (2.3M) | (6.5M) |